BSG and non-small cell lung carcinoma: To confirm the mechanistic association between CypA/CD147 and EGFR in NSCLC CSCs, we assessed whether treatment with afatinib, a second-generation EGFR TKI, affected the expression levels of CypA and CD147 in NCI-H1650- and HCC827-derived CSCs.